在阿根廷老年人中引入MF59佐剂三价流感疫苗的成本效果
本研究评估阿根廷65岁以上老年人中,用MF59佐剂三价流感疫苗(aTIV)替代现行非佐剂三价流感疫苗(TIV)的成本效果。决策树模型显示,换用aTIV可避免170例死亡并获得1310个质量调整生命年(QALY),每QALY增量成本效果比为2660.59美元,概率敏感性分析95%CI为113.74-7721.67美元。结论认为引入aTIV相对现行TIV可能有益且具成本效果。
要点
- 阿根廷65岁以上成人流感相关疾病负担高,年均流感样病例率3500/10万、住院率15.5/10万、死亡率0.32/10万。
- 换用aTIV预计可避免170例死亡,获得1310个QALY增量。
- 每QALY增量成本效果比为2660.59美元,所有敏感性分析中aTIV均保持高度成本效果。
核心结论
- 在阿根廷老年人中引入aTIV相对现行TIV可能有益且具成本效果,可减轻疾病负担和医疗资源利用。
研究设计与样本
- 决策树成本效果模型,从支付方角度比较一个流感季节内接种aTIV与TIV的成本和健康收益。
- 模型输入来自阿根廷或国际数据(当地数据被认为不准确时),疫苗效力假设取自近期发表的同行评议文献。
- 主要预测包括生存、质量调整生存和成本。
主要发现
- 从TIV换用aTIV可避免170例死亡,获得1310个QALY增量。
- 每QALY增量成本效果比为2660.59美元(支付方角度)。
- 概率敏感性分析显示每QALY的95%CI为113.74-7721.67美元。
- 在所有敏感性分析中aTIV均保持高度成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Influenza surveillance in Argentina reported influenza-like illness at a rate of 3500/100,000, a hospitalization rate of 15.5/100,000, and a death rate of 0.32/100,000 annually in adults aged over 65 years. The high burden of disease may be due to a combination of immunosenescence and the suboptimal clinical effectiveness of conventional, non-adjuvanted influenza vaccines in this age group. There is a clinical need for more effective influenza vaccines in this population. This study evaluated the cost-effectiveness of an MF59®-adjuvanted trivalent influenza vaccine (aTIV) in adults aged over 65 years in Argentina compared with the non-adjuvanted trivalent influenza vaccine (TIV) used under the current national vaccination policy. METHODS: A decision tree cost-effectiveness model was developed to estimate the cost-effectiveness of switching from TIV to aTIV in Argentinian older adults. The model compared cost and health benefits of vaccination in one influenza season from the payer perspective. The main predictions included survival, quality-adjusted survival, and costs. Model inputs were sourced from Argentina or internationally where local data was considered inaccurate. Vaccine efficacy assumptions were extracted from recently published, peer-reviewed scientific literature. RESULTS: Switching from TIV to aTIV would result in 170 deaths averted and 1310 incremental quality-adjusted life years (QALYs) gained. The incremental cost-effectiveness ratio per QALY was US $2660.59 from the payer perspective. In all sensitivity analyses, aTIV remained highly cost-effective. The probabilistic sensitivity analyses showed a 95% CI per QALY of US $113.74-7721.67. CONCLUSION: Introducing an adjuvanted influenza vaccine in Argentina is potentially beneficial and cost-effective relative to the currently-used TIV through the reduction of disease burden and utilization of healthcare resources.
引用
- Nguyen VH, Vizzotti C, Uruena A, et al. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina. Vaccine. 2020. PMID: 32249017. doi:10.1016/j.vaccine.2020.02.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。